{
    "clinical_study": {
        "@rank": "48485", 
        "arm_group": {
            "arm_group_label": "Refametinib (BAY86-9766)+ Gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, uncontrolled, Phase Ib study designed to evaluate the safety,\n      tolerability, and pharmacokinetics of BAY86-9766 when given as a single agent and in\n      combination with gemcitabine in Asian patients with advanced or refractory solid\n      tumors.Blood samples for PK (pharmacokinetics) analyses will be collected after a single\n      dose of BAY86-9766, multiple doses of BAY86-9766, and combination treatment of gemcitabine\n      and BAY86-9766.\n\n      Safety evaluation will include adverse events assessment, vital signs, laboratory tests,\n      12-lead ECG ECG (electrocardiography), cardiac function test, and ophthalmologic examination\n      at various time points during the study."
        }, 
        "brief_title": "BAY86-9766 Plus Gemcitabine Phase I Study in Asian", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients >/= 18 years of age, with histologically or cytologically\n             documented advanced or refractory solid tumors not amenable to standard therapy\n\n          -  Patients must have at least one measurable or evaluable tumor lesion according to\n             Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n\n          -  Patients must have a life expectancy of at least 12 weeks, and an Eastern Cooperative\n             Oncology Group Performance Status (ECOG PS) </=1.\n\n        Exclusion Criteria:\n\n          -  History of cardiac disease\n\n          -  Active clinically serious infections > Common Terminology Criteria for Adverse Events\n             (CTCAE) grade 2\n\n          -  Known human immunodeficiency virus (HIV) infection\n\n          -  Uncontrolled seizure disorder\n\n          -  Undergoing renal dialysis\n\n          -  Known bleeding diathesis\n\n          -  History of organ allograft\n\n          -  Pregnant or breast feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764828", 
            "org_study_id": "14747"
        }, 
        "intervention": [
            {
                "arm_group_label": "Refametinib (BAY86-9766)+ Gemcitabine", 
                "intervention_name": "Refametinib (BAY86-9766)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Refametinib (BAY86-9766)+ Gemcitabine", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase I", 
            "Pharmacokinetics", 
            "Safety measurements"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-8577"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul Teugbyeolsi", 
                        "zip": "110-744"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "China: Food and Drug Administration", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma concentration of BAY86-9766", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 6 day"
            }, 
            {
                "measure": "Plasma concentration of M17 and M11", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 6 day"
            }, 
            {
                "measure": "Plasma concentration of Gemcitabine", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 6 day"
            }, 
            {
                "measure": "Plasma concentration of dFdU", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 6 day"
            }, 
            {
                "description": "Parameters are laboratory parameters, vital signs, ECG parameters, cardiac function, and parameters of ophthalmologic examinations", 
                "measure": "Number of adverse events, or abnormal parameters as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Elements of the scale are :Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD)", 
            "measure": "Efficacy of BAY86-9766 shown by a discrete scale", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}